$EXAS News

EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum

Amalgam Announces Privia Health-Led Colorectal Cancer Screening Program Demonstrates 84% Screening Rates In 2024, Surpassing 80% Goal

Exact Sciences Earnings Review: Q4 Summary

Exact Sciences Q4 Adj. EPS $(0.21) Misses $(0.07) Estimate, Sales $878.381M Beat $860.895M Estimate

Soft Start For $10B-Plus M&A Deals In 2026

Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time.

1 Momentum Stock with Exciting Potential and 2 Facing Headwinds

Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings?

Exact Sciences Milestone In Breast Cancer Genomics And What It Means For EXAS

1 Growth Stock to Stash and 2 We Avoid

Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025

Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement

A Look At Exact Sciences (EXAS) Valuation After Its Strong Recent Share Price Momentum

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Assessing Exact Sciences: Insights From 16 Financial Analysts

Mizuho Downgrades Exact Sciences to Neutral, Raises Price Target to $105

Evercore ISI Group Downgrades Exact Sciences to In-Line, Maintains Price Target to $105

Celldex Therapeutics Stock Gets RS Rating Lift